Twenty seven out of 32 economists polled in advance anticipated a 25 basis point easing from the Royal Bank of Australia but, in a surprise move, it opted to stand pat at 3.86% this time round. Govern ...

Super Group has upgraded its guidance for the year and said that it plans to exit the U.S. as it looks to streamline its operations. The online sports betting and gaming businesses company said ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

U.S. government debt will face a crucial test from investors this week as it readies a series of Treasury auctions ...

WeightWatchers’ stock was surging after the company emerged from bankruptcy two months after it was announced.

Goldman say resilient earnings, earlier and bigger Fed rate cuts and more investor buying of stocks will drive the S&P 500 ...

Pressure on the U.S. Treasury market continued Tuesday morning, with long-end rates on pace to march higher for a fifth straight session. This comes as investors await a $58 billion of 3-year paper on ...

Cellebrite DI said Tuesday that it has appointed David Barter as its new chief financial officer, effective immediately. Barter succeeds Dana Gerner, who has served as Cellebrite's CFO since 2014.

Stagwell named Ryan Greene as chief financial officer. The media and public relations agency also appointed Frank Lanuto as executive vice president, finance, Jason Reid as chief strategy officer, and ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...